| Literature DB >> 28274961 |
Sophia Morel1,2, Jade Leahy1,2, Maryse Fournier1,2, Benoit Lamarche3, Carole Garofalo1, Guy Grimard4, Floriane Poulain1, Edgard Delvin1, Caroline Laverdière1,4, Maja Krajinovic1,4, Simon Drouin1, Daniel Sinnett1,4, Valérie Marcil1,2, Emile Levy5,2,3.
Abstract
Survivors of acute lymphoblastic leukemia (ALL), the most common cancer in children, are at increased risk of developing late cardiometabolic conditions. However, the mechanisms are not fully understood. This study aimed to characterize the plasma lipid profile, Apo distribution, and lipoprotein composition of 80 childhood ALL survivors compared with 22 healthy controls. Our results show that, despite their young age, 50% of the ALL survivors displayed dyslipidemia, characterized by increased plasma triglyceride (TG) and LDL-cholesterol, as well as decreased HDL-cholesterol. ALL survivors exhibited lower plasma Apo A-I and higher Apo B-100 and C-II levels, along with elevated Apo C-II/C-III and B-100/A-I ratios. VLDL fractions of dyslipidemic ALL survivors contained more TG, free cholesterol, and phospholipid moieties, but less protein. Differences in Apo content were found between ALL survivors and controls for all lipoprotein fractions except HDL3 HDL2, especially, showed reduced Apo A-I and raised Apo A-II, leading to a depressed Apo A-I/A-II ratio. Analysis of VLDL-Apo Cs disclosed a trend for higher Apo C-III1 content in dyslipidemic ALL survivors. In conclusion, this thorough investigation demonstrates a high prevalence of dyslipidemia in ALL survivors, while highlighting significant abnormalities in their plasma lipid profile and lipoprotein composition. Special attention must, therefore, be paid to these subjects given the atherosclerotic potency of lipid and lipoprotein disorders.Entities:
Keywords: apolipoproteins; atherosclerosis; cancer; cardiovascular diseases; clinical studies; dyslipidemia; lipid and lipoprotein metabolism; metabolic syndrome
Mesh:
Substances:
Year: 2017 PMID: 28274961 PMCID: PMC5408606 DOI: 10.1194/jlr.M072207
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922